Back to Agenda
Facilitating Access: Patient Perspectives on a Streamlined Development Approach for Treatments for Severely-Debilitating or Life-Threatening Diseases
Session Chair(s)
Judith Prescott, DVM, PhD
Executive Director, Safety Assessment
Merck & Co., Inc., United States
This forum will introduce a streamlined approach to the development of therapies to address severely-debilitating or life threatening diseases and consider the potential value of global regulatory guidance.
Learning Objective : Discuss the use of streamlined development programs to expeditiously deliver promising new treatments to patients with severely debilitating or life-threatening diseases from the patient perspective.
Speaker(s)
Proposal for Development of Pharmaceuticals for Severly-Debilitating or Life Threatening Indications
Judith Prescott, DVM, PhD
Merck & Co., Inc., United States
Executive Director, Safety Assessment
Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Considerations
Haleh Saber, PhD
FDA, United States
Deputy Director, DHOT/ OHOP/ CDER
Perspective from The Patients' Academy For Research Advocacy
Susan Schaeffer
The Patients' Academy For Research Advocacy, United States
President and Chief Executive Officer
Panelist
Catherine Kopil, PhD
The Michael J. Fox Foundation for Parkinson's Research, United States
Director, Research Partnerships
Panelist
Isabelle Lousada, MA
Amyloidosis Research Consortium, United States
Chief Executive Officer and President
Have an account?